# Juri Biosciences, Inc.: Phase 1 study started recruiting, 210 planned (Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC))

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | Juri Biosciences, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | JUR-003 in Adult Patients With Metastatic Prostate Cancer |
| NCT ID | NCT07824349 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Metastatic Castration Resistant Prostate Cancer; Oligometastatic Prostate Cancer (OMPC); Metastatic Hormone Sensitive Prostate Cancer |
| Intervention types | biological |
| Target enrollment | 210 |
| Site countries | United States |
| Posted | 2026-09-17 |
| Planned start | 2026-10-26 |
| Event | Started recruiting |
| Event date | 2026-10-26 |
| Last update posted | 2026-11-04 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- 210 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07824349). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.